[1] 陈媛媛, 刘旭辉, 侯明杰,等. 58例艾滋病合并马尔尼菲青霉菌病病人临床特征分析[J]. 中国艾滋病性病, 2018(1):30-32.
[2] Qin L, Zhao L, Tan C, et al. A novel method of combining Periodic Acid Schiff staining with Wright-Giemsa staining to identify the pathogens Penicillium marneffei, Histoplasma capsulatum, Mucor and Leishmania donovani in bone marrowsmears[J]. Exp Ther Med, 2015, 9(5):1950-1954.
[3] Samson RA,Yilmaz N,Houbraken J,et al. Phylogeny and nomenclature of the genus Talaromyces and taxa accommodated in Penicillium subgenus Biverticillium[J]. Stud Mycol,2011,70(1):159-183.
[4] Capponi M, Segretain G, Sureau P. Penicillosis from Rhizomys sinensis[J]. Bull Soc Pathol Exot Filiales, 1956, 49(3):418-421.
[5] Li X, Yang Y, Zhang X, et al. Isolation of Penicillium marneffei from soil and wild rodents in Guangdong, SE China[J]. Mycopathologia, 2011, 172(6):447-451.
[6] Weerasinghe H, Payne M, Beard S, et al. Organism-wide studies into pathogenicity and morphogenesis in Talaromyces marneffei[J]. Future Microbiology, 2016, 11(4):511-526.
[7] Pasricha S, Macrae J I, Chua H H, et al. Extensive Metabolic Remodeling Differentiates Non-pathogenic and Pathogenic Growth Forms of the Dimorphic Pathogen Talaromyces marneffei[J]. Front Cell Infect Microbiol, 2017, 7:368.
[8] Le T, Wolbers M, Chi N H, et al. Epidemiology, Seasonality, and Predictors of Outcome of AIDS-Associated Penicillium marneffei Infection in Ho Chi Minh City, Viet Nam[J]. Clin Infect Dis, 2011, 52(7):945-952.
[9] Vanittanakom N, Jr CC, Fisher MC, et al. Penicillium marneffei infection and recent advances in the epidemiology and molecular biology aspects[J]. Clinical Microbiology Reviews, 2006, 19(1):95-110.
[10] Li HR, Cai SX, Chen YS, et al. Comparison of Talaromyces marneffeiInfection in Human Immunodeficiency Virus-positive and Human Immunodeficiency Virus-negative Patients from Fujian, China[J]. 中华医学杂志(英文版), 2016, 129(9):1059-1065.
[11] 赵亮, 唐秀文, 王梅竹,等. 中国南方地区马尔尼菲青霉分子流行病学初步研究[J]. 中国人兽共患病学报, 2014, 30(1):36-39.
[12] Pruksaphon K, Intaramat A, Ratanabanangkoon K,et al.Development and characterization of an immunochromatographic test for the rapid diagnosis of Talaromyces (Penicillium) marneffei[J]. PLoS One. 2018;13(4):e0195596.
[13] Ning C,Lai J, Wei W,et al. Accuracy of rapid diagnosis of Talaromyces marneffei:A systematic review and meta-analysis[J].Plos One.2018,13(4):e01995569.
[14] 杨艳秋, 徐红英, 汪林娇. 72例AIDS患者深部真菌感染的菌种分布及耐药分析[J]. 中国医药指南, 2016, 14(10):123-124.
[15] Hee CH, PilCY, Cho K J. Penicillium marneffei infection in a HIV-Positive patient:A comparison of bronchial washing cytology and biopsy[J]. J Cytol, 2017, 34(1):45-48.
[16] Pongpom M, Vanittanakom P, Nimmanee P, et al. Adaptation to macrophage killing by Talaromyces marneffei[J]. Future Sci OA, 2017, 3(3):FSO215.
[17] Chen J, Zhang R, Shen Y, et al. Clinical Characteristics and Prognosis of Penicilliosis Among Human Immunodeficiency Virus-Infected Patients in Eastern China[J]. Am J Trop Med Hyg, 2017, 96(6):1350-1354.
[18] Kawila R, Chaiwarith R, Supparatpinyo K. Clinical and laboratory characteristics of penicilliosis marneffei among patients with and without HIV infection in Northern Thailand:a retrospective study[J]. Bmc Infectious Diseases, 2013, 13(1):464-464.
[19] 莫让辉, 李论, 陆鹏,等. 骨髓培养在艾滋病合并马尔尼菲青霉菌病诊疗中的价值[J]. 临床荟萃, 2014(8):920-922.
[20] 朱彤. PAS联合六胺银染色诊断局限性马尔尼菲青霉菌感染的应用[J]. 热带医学杂志, 2012, 12(8):912,945-947,961.
[21] Nong S, Liang J. Bone marrow Penicillium marneffei infection in acquired immunodeficiency syndrome patients:report of 35 cases[J]. Trop Biomed, 2013, 30(1):89-91.
[22] 陈蓉, 张立新, 刘婷,等. 多学科合作对马尔尼菲青霉病快速诊断的价值[J]. 中国艾滋病性病, 2017(4):334-336.
[23] Chen J, Zhang R, Shen Y, et al. Clinical Characteristics and Prognosis of Penicilliosis Among Human Immunodeficiency Virus-Infected Patients in Eastern China.[J]. Am J Trop Med Hyg, 2017, 96(6):1350-1354.
[24] Zheng J, Gui X, Cao Q, et al. A Clinical Study of Acquired Immunodeficiency Syndrome Associated Penicillium marneffei Infection from a Non-Endemic Area in China[J]. Plos One, 2015, 10(6):e0130376.
[25] 彭帆, 钟正, 孔祥龙,等. 22例艾滋病合并马尔尼菲篮状菌感染患者的临床特征[J]. 中国感染控制杂志, 2018,17(7):610-614.
[26] 胡家光,蒋忠胜,温小凤,等. 运用ROC曲线评价血清氨基转移酶在播散性马尔尼菲青霉菌病诊断中的价值[J]. 中国皮肤性病学杂志, 2015(8):802-804.
[27] Le T, Kinh NV, Ntk C, et al. A Trial of Itraconazole or Amphotericin B for HIV-Associated Talaromycosis.[J]. N Engl J Med, 2017, 376(24):2329-2340.
[28] 陈秀芳, 周燕华, 刘栋华,等. 两性霉素B联合曲酸作用于马尔尼菲青霉的体外药敏实验[J]. 中国皮肤性病学杂志, 2015(11):1123-1126.
[29] Lau SK, Lo GC, Lam CS, et al. In Vitro Activity of Posaconazole against Talaromyces marneffei by Broth Microdilution and Etest Methods and Comparison to Itraconazole, Voriconazole, and Anidulafungin[J]. Antimicrob Agents Chemother, 2016, 61(3):e01480-16.
[30] Zeng W, Qiu Y, Lu D, et al. A Retrospective Analysis of 7 Human Immunodeficiency Virus-Negative Infants Infected by Penicillium marneffei[J]. Medicine, 2015, 94(34):e1439.
[31] Chariyalertsak S, Supparatpinyo K, Sirisanthana T, et al. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand[J]. Clin Infect Dis, 2002, 34(2):277-284.
[32] Ouyang Y, Cai S, Liang H, et al. Administration of Voriconazole in Disseminated Talaromyces (Penicillium) Marneffei Infection:A Retrospective Study[J]. Mycopathologia, 2017, 182(5):1-7.
[33] Dabis F, Bekker LG. We still need to beat HIV[J]. Science,2017,357(6349):335.
[34] 中国疾病预防控制中心性病艾滋病预防控制中心性病控制中心. 2017年12月全国艾滋病性病疫情[J]. 中国艾滋病性病, 2018,24(2):111.
[35] Qiu Y, Tang Y, Zhang J, et al. A Retrospective Analysis of Seven Patients with Acquired Immunodeficiency Syndrome and Pharyngeal and/or Laryngeal Talaromyces marneffei Infection[J]. Clin Otolaryngol, 2017,42(5):1061-1066.